Harout Semerjian

Harout Semerjian is the current President & CEO at GlycoMimetics. Prior to this, they served as President & Chief Executive Officer at Immunomedics from April 2020 to May 2020. From February 2017 to April 2020, they were EVP & Chief Commercial Officer at Ipsen. And from October 2016 to February 2017, they were Senior Vice President and Global Launch Lead, Ribociclib at Novartis Oncology. Harout Semerjian has also served as Vice President and Hematology Business Franchise Head at Novartis from February 2007 to October 2016.

Semerjian earned their MBA in general management from the Cornell Johnson Graduate School of Management and their Bachelor of Science in biology from the Lebanese American University.

Some individuals on their team include Bryan Ridgell - VP, Portfolio & Project Management, Brian Hahn - CFO & SVP, and Armand Girard - CBO & SVP, Strategy & Corporate Development.